S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
Log in
OTCMKTS:AMBS

Amarantus BioScience Stock Forecast, Price & News

$0.02
+0.00 (+9.29 %)
(As of 03/2/2021 03:57 PM ET)
Add
Compare
Today's Range
$0.01
Now: $0.02
$0.02
50-Day Range
$0.01
MA: $0.01
$0.02
52-Week Range
$0.00
Now: $0.02
$0.02
Volume472,410 shs
Average Volume1.04 million shs
Market Capitalization$5.64 million
P/E RatioN/A
Dividend YieldN/A
Beta1
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:AMBS
CUSIPN/A
CIKN/A
Phone650-862-5391
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$5.64 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1934th out of 1,968 stocks

Pharmaceutical Preparations Industry

763rd out of 772 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.02
+0.00 (+9.29 %)
(As of 03/2/2021 03:57 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMBS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMBS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amarantus BioScience (OTCMKTS:AMBS) Frequently Asked Questions

What stocks does MarketBeat like better than Amarantus BioScience?

Wall Street analysts have given Amarantus BioScience a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amarantus BioScience wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Amarantus BioScience's key executives?

Amarantus BioScience's management team includes the following people:
  • Mr. Gerald E. Commissiong, CEO, Pres & Director (Age 38)
  • Dr. John Wesley Commissiong, Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 76)
  • Mr. Robert Lewis Harris, Compliance Officer & Director (Age 77)
  • Dr. Elise Brownell, Sr. VP of Operations & Project Management
  • Aimee Boutcher, Director of Investor Relations
  • Dr. Ravi Kiron, Sr. VP of Bus. Devel. (Age 61)
  • Dr. Paula T. Trzepacz, Chief Medical Advisor to Elto Pharma and Breakthrough Diagnostics
  • Dr. Brian E. Harvey, Chief Regulatory Advisor & Member of Board of Advisors
  • Dr. Richard Kagan M.D., Chief Medical Advisor to Cutanogen Corp.
  • Dr. Owen Garrick, Corp. Advisor

Who are some of Amarantus BioScience's key competitors?

What other stocks do shareholders of Amarantus BioScience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarantus BioScience investors own include CenterPoint Energy (CNP), Adient (ADNT), Everbridge (EVBG), Ford Motor (F), Kellogg (K), The Kraft Heinz (KHC), Kratos Defense & Security Solutions (KTOS), MetLife (MET), NVIDIA (NVDA) and AT&T (T).

What is Amarantus BioScience's stock symbol?

Amarantus BioScience trades on the OTCMKTS under the ticker symbol "AMBS."

How do I buy shares of Amarantus BioScience?

Shares of AMBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amarantus BioScience's stock price today?

One share of AMBS stock can currently be purchased for approximately $0.01.

How much money does Amarantus BioScience make?

Amarantus BioScience has a market capitalization of $5.16 million.

What is Amarantus BioScience's official website?

The official website for Amarantus BioScience is www.amarantus.com.

Where are Amarantus BioScience's headquarters?

Amarantus BioScience is headquartered at 655 MONTGOMERY STREET SUITE 900, SAN FRANCISCO CA, 94111.

How can I contact Amarantus BioScience?

Amarantus BioScience's mailing address is 655 MONTGOMERY STREET SUITE 900, SAN FRANCISCO CA, 94111. The company can be reached via phone at 650-862-5391 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.